Protagenic says PT00114 cuts corticosterone, anxiety-like behavior in chronic stress rat study

Protagenic Therapeutics, Inc.

PTIX

0.00

Protagenic Therapeutics disclosed published preclinical results for PT00114 in a peer-reviewed journal; findings have already been presented in print.
The drug lowered biological stress signals, improved anxiety-like behavior in chronically stressed rats, without signs of sedation-related effects.
A benchmark CRF1 antagonist failed to show benefit in the same chronic-stress model, supporting PT00114’s differentiated mechanism.
Protagenic cited positive Phase 1 safety topline results, positioning PT00114 for additional clinical studies planned for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606300830ACCESSWRNAPR_____1183792) on June 30, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.